year,year_approval_count,drug_name,active_ingredient,approval_date,approved_use,drug_link,press_release,drug_trials_snapshot
2012,1,Voraxaze,glucarpidase,2012-01-17,To treat patients with toxic levels of methotrexate in their blood due to kidney failure. Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125327&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm287997.htm,
2012,2,Picato,ingenol mebutate,2012-01-23,For the topical treatment of actinic keratosis.,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202833&SearchType=BasicSearch,,
2012,3,Inlyta,axitinib,2012-01-27,To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202324&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289423.htm,
2012,4,Erivedge,vismodegib,2012-01-30,"To treat adult patients with basal cell carcinoma, the most common type of skin cancer.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203388&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289545.htm,
2012,5,Kalydeco,ivacaftor,2012-01-31,For the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. Press Release,,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm,
2012,6,Zioptan,tafluprost,2012-02-10,For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202514&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291966.htm,
2012,7,Surfaxin,lucinactant,2012-03-06,"For the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=021746&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294984.htm,
2012,8,Omontys,peginesatide,2012-03-27,"To treat anemia, a condition in which the body does not have enough healthy red blood cells, in adult dialysis patients who have chronic kidney disease (CKD).Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202799&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm,
2012,9,Amyvid,Florbetapir F 18,2012-04-06,Used as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202008&SearchType=BasicSearch,,
2012,10,Stendra,avanafil,2012-04-27,To treat erectile dysfunction.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202276&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm,
2012,11,Elelyso,taliglucerase alfa,2012-05-01,"For long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorderPress Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022458&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302549.htm,
2012,12,Perjeta,pertuzumab,2012-06-08,To treat patients with HER2-positive late-stage (metastatic) breast cancer.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125409&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm307549.htm,
2012,13,Belviq,lorcaserin hydrochloride,2012-06-27,For chronic weight management.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022529&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm,
2012,14,Myrbetriq,mirabegron,2012-06-28,To treat adults with overactive bladder.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202611&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310096.htm,
2012,15,Prepopik,"sodium picosulfate, magnesium oxide and citric acid",2012-07-16,To help cleanse the colon in adults preparing for colonoscopy.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202535&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312315.htm,
2012,16,Kyprolis,carfilzomib,2012-07-20,"To treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202714&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312920.htm,
2012,17,Tudorza Pressair,aclidinium bromide,2012-07-23,"For the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202450&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm313052.htm,
2012,18,Zaltrap,ziv-aflibercept,2012-08-03,"For use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer. Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125418&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm314372.htm,
2012,19,Stribild,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",2012-08-27,A once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203100&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317004.htm,
2012,20,Neutroval,tbo-filgrastim,2012-08-29,"To reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125294&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm,
2012,21,Linzess,linaclotide,2012-08-30,To treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults. Press Release,,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm,
2012,22,Xtandi,enzalutamide,2012-08-31,"To treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203415&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317838.htm,
2012,23,Bosulif,bosutinib,2012-09-04,"To treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203341&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm318160.htm,
2012,24,Aubagio,teriflunomide,2012-09-12,For the treatment of adults with relapsing forms of multiple sclerosis (MS).Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202992&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm,
2012,25,Choline C 11 Injection,Choline C 11 Injection,2012-09-12,A Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203155&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm,
2012,26,Stivarga,regorafenib,2012-09-27,To treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203085&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321271.htm,
2012,27,Jetrea,ocriplasmin,2012-10-17,To treat an eye condition called symptomatic vitreomacular adhesion (VMA).Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125422&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm324369.htm,
2012,28,Fycompa,perampanel,2012-10-22,To treat partial onset seizures in patients with epilepsy ages 12 years and older.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202834&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325038.htm,
2012,29,Synribo,omacetaxine mepesuccinate,2012-10-26,"To treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203585&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325895.htm,
2012,30,Xeljanz,tofacitinib,2012-11-06,"To treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203214&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm,
2012,31,Cometriq,cabozantinib,2012-11-29,To treat medullary thyroid cancer that has spread to other parts of the body (metastasized).Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203756&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm,
2012,32,Iclusig,ponatinib,2012-12-14,"To treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203469&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm,
2012,33,raxibacumab,raxibacumab,2012-12-14,"To treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125349&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm,
2012,34,Signifor,pasereotide,2012-12-14,To treat Cushing’s disease patients who cannot be helped through surgeryPress Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=200677&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm,
2012,35,Gattex,teduglutide,2012-12-21,To treat adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding (parenteral nutrition).Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203441&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333171.htm,
2012,36,Juxtapid,lomitapide,2012-12-21,"To reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203858&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm,
2012,37,Eliquis,apixaban,2012-12-28,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202155&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm,
2012,38,Sirturo,bedaquiline,2012-12-28,As part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available.Press Release,https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204384&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm,
2012,39,Fulyzaq,crofelemer,2012-12-31,"To treat HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite. Press Release",https://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202292&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052138/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm,
2013,1,Nesina,alogliptin,2013-01-25,To improve blood sugar control in adults with type 2 diabetes.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022271&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm,
2013,2,Kynamro,mipomersen sodium,2013-01-29,To treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203568&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm,
2013,3,Pomalyst,pomalidomide,2013-02-08,To treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204026&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm338895.htm,
2013,4,Kadcyla,ado-trastuzumab emtansine,2013-02-22,"For patients with HER2-positive, late-stage (metastatic) breast cancer.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125427&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm,
2013,5,Osphena,ospemifene,2013-02-26,"To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203505&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm341128.htm,
2013,6,Lymphoseek,technetium Tc 99m tilmanocept,2013-03-13,A radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202207&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm343525.htm,
2013,7,Dotarem,gadoterate meglumine,2013-03-20,"For use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204781&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm344758.htm,
2013,8,Tecfidera,dimethyl fumarate,2013-03-27,To treat adults with relapsing forms of multiple sclerosis (MS).Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204063&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345528.htm,
2013,9,Invokana,canagliflozin,2013-03-29,"Used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204042&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm,
2013,10,Breo Ellipta,fluticasone furoate and vilanterol inhalation powder,2013-05-10,"For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204275&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm,
2013,11,Xofigo,radium Ra 223 dichloride,2013-05-15,To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203971&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352363.htm,
2013,12,Tafinlar,dabrafenib,2013-05-29,To treat patients with melanoma whose tumors express the BRAF V600E gene mutation.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202806&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm,
2013,13,Mekinist,trametinib,2013-05-29,To treat patients whose tumors express the BRAF V600E or V600K gene mutations. Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204114&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm,
2013,14,Gilotrif,afatinib,2013-07-12,"For patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=201292&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm360499.htm,
2013,15,Tivicay,dolutegravir,2013-08-12,To treat HIV-1 infection.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204790&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm,
2013,16,Brintellix,vortioxetine,2013-09-30,To treat adults with major depressive disorder.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204447&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370416.htm,
2013,17,Duavee,conjugated estrogens/bazedoxifene,2013-10-03,To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause.Web Posting,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022247&SearchType=BasicSearch,,
2013,18,Adempas,riociguat,2013-10-08,To treat adults with two forms of pulmonary hypertension.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204819&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370866.htm,
2013,19,Opsumit,macitentan,2013-10-18,"To treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204410&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm371362.htm,
2013,20,Vizamyl,flutemetamol F 18 injection,2013-10-25,A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203137&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm,
2013,21,Gazyva,obinutuzumab,2013-11-01,For use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125486&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm,
2013,22,Aptiom,eslicarbazepine acetate,2013-11-08,As an add-on medication to treat seizures associated with epilepsy.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022416&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374358.htm,
2013,23,Imbruvica,ibrutinib,2013-11-13,"To treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.Press Release",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=205552&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374761.htm,
2013,24,Luzu,luliconozole,2013-11-14,"For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.",https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204153&SearchType=BasicSearch,,
2013,25,Olysio,simeprevir,2013-11-22,To treat chronic hepatitis C virus infection.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=205123&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm,
2013,26,Sovaldi,sofosbuvir,2013-12-06,To treat chronic hepatitis C virus (HCV) infection.Press Release,https://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204671&SearchType=BasicSearch,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm,
2013,27,Anoro Ellipta,umeclidinium and vilanterol inhalation powder,2013-12-18,"For the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).Press Release",,https://wayback.archive-it.org//7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm379057.htm,
2014,1,Farxiga,dapaglifozin,2014-01-08,"To improve glycemic control, along with diet and exercise, in adults with type 2 diabetesPress Release",https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=202293&DrugName=FARXIGA&ActiveIngred=DAPAGLIFLOZIN&SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm,
2014,2,Hetlioz,tasimelteon,2014-01-31,To treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep.Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205677&DrugName=HETLIOZ&ActiveIngred=TASIMELTEON&SponsorApplicant=VANDA%20PHARMACEUTICALS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm384092.htm,
2014,3,Vimizim,elosulfase alfa,2014-02-14,Treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125460&DrugName=VIMIZIM&ActiveIngred=ELOSULFASE%20ALFA&SponsorApplicant=BIOMARIN%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm386008.htm,
2014,4,Northera,droxidopa,2014-02-18,To treat neurogenic orthostatic hypotension (NOH)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203202&DrugName=NORTHERA&ActiveIngred=DROXIDOPA&SponsorApplicant=CHELSEA%20THERAPS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm386311.htm,
2014,5,Myalept,metreleptin for injection,2014-02-24,To treat the complications of leptin deficiencyPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125390&DrugName=MYALEPT&ActiveIngred=METRELEPTIN&SponsorApplicant=AMYLIN%20PHARMS%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm387060.htm,
2014,6,Neuraceq,florbetaben F 18 injection,2014-03-19,For Positron EmissionTomography (PET) imaging of the brain,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204677&DrugName=NEURACEQ&ActiveIngred=FLORBETABEN%20F%2D18&SponsorApplicant=PIRAMAL%20IMAGING&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,7,Impavido,miltefosine,2014-03-19,To treat a tropical disease called leishmaniasisPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204684&DrugName=IMPAVIDO&ActiveIngred=MILTEFOSINE&SponsorApplicant=PALADIN%20THERAP&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm389671.htm,
2014,8,Otezla,apremilast,2014-03-21,To treat adults with active psoriatic arthritis (PsA)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205437&DrugName=OTEZLA&ActiveIngred=APREMILAST&SponsorApplicant=CELGENE%20CORP&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm390091.htm,
2014,9,Tanzeum,albiglutide,2014-04-15,"To improve glycemic control, along with diet and exercise, in adults with type 2 diabetesPress Release",https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125431&DrugName=TANZEUM&ActiveIngred=ALBIGLUTIDE&SponsorApplicant=GLAXOSMITHKLINE%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm,
2014,10,Cyramza,ramucirumab,2014-04-21,To treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinomaPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125477&DrugName=CYRAMZA&ActiveIngred=RAMUCIRUMAB&SponsorApplicant=ELI%20LILLY%20AND%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm,
2014,11,Sylvant,siltuximab,2014-04-23,"To treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes)Press Release",https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125496&DrugName=SYLVANT&ActiveIngred=SILTUXIMAB&SponsorApplicant=JANSSEN%20BIOTECH&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm,
2014,12,Zykadia,ceritinib,2014-04-29,To treat patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205755&DrugName=ZYKADIA&ActiveIngred=CERITINIB&SponsorApplicant=NOVARTIS%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm,
2014,13,Zontivity,vorapaxar,2014-05-08,To reduce the risk of heart attacks and stroke in high-risk patientsPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204886&DrugName=ZONTIVITY&ActiveIngred=VORAPAXAR%20SULFATE&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm,
2014,14,Entyvio,vedolizumab,2014-05-20,To treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s diseasePress ReleaseDrug Trials Snapshot (Crohn's Disease)Drug Trials Snapshot (ulcerative colitis),https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125476&DrugName=ENTYVIO&ActiveIngred=VEDOLIZUMAB&SponsorApplicant=TAKEDA%20PHARMS%20USA&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398065.htm,
2014,15,Dalvance,dalbavancin,2014-05-23,To treat adults with skin infectionsPress Release Drug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=021883&DrugName=DALVANCE&ActiveIngred=DALBAVANCIN%20HYDROCHLORIDE&SponsorApplicant=DURATA%20THERAPS%20INTL&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htm,
2014,16,Jublia,efinaconazole,2014-06-06,Treat mild to moderate onychomycosis (fungal infection) No Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203567&DrugName=JUBLIA&ActiveIngred=EFINACONAZOLE&SponsorApplicant=DOW%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,17,Sivextro (tablet)Sivextro (injection),tedizolid phosphate,2014-06-20,To treat adults with skin infectionsPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205435&DrugName=SIVEXTRO&ActiveIngred=TEDIXOLID%20PHOSPHATE&SponsorApplicant=CUBIST%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm402174.htm,
2014,18,Beleodaq,belinostat,2014-07-03,To treat patients with peripheral T-cell lymphoma (PTCL) Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206256&DrugName=BELEODAQ&ActiveIngred=BELINOSTAT&SponsorApplicant=SPECTRUM%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm,
2014,19,Kerydin,tavaborole,2014-07-07,For the topical treatment of onychomycosis of the toenails (No Press Release),https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204427&DrugName=KERYDIN&ActiveIngred=TAVABOROLE&SponsorApplicant=ANACOR%20PHARMS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,20,Zydelig,idelalisib,2014-07-23,To treat patients with trhee types of blood cancersPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206545&DrugName=ZYDELIG&ActiveIngred=IDELALISIB&SponsorApplicant=GILEAD%20SCIENCES%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm,
2014,21,Striverdi Respimat,olodaterol,2014-07-31,To treat chronic obstructive pulmonary diseasePress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203108&DrugName=Striverdi%20Respimat&ActiveIngred=Olodaterol%20Respimat&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407465.htm,
2014,22,Jardiance,empagliflozin,2014-08-01,To improve gylcemic control in adults with type 2 diabetesPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204629&DrugName=JARDIANCE&ActiveIngred=EMPAGLIFLOZIN&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm,
2014,23,Orbactiv,oritavancin,2014-08-06,To treat adults with skin infectionsPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206334&DrugName=ORBACTIV&ActiveIngred=ORITAVANCIN%20DIPHOSPHATE&SponsorApplicant=MEDICINES%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm408475.htm,
2014,24,Belsomra,suvorexant,2014-08-13,To treat difficulty in falling and staying asleep (insomnia)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204569&DrugName=BELSOMRA&ActiveIngred=SUVOREXANT&SponsorApplicant=MERCK%20AND%20CO%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm,
2014,25,Plegridy,peginterferon beta-1a,2014-08-15,For the treatment of patients with relapsing forms of multiple sclerosis,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125499&DrugName=PLEGRIDY&ActiveIngred=PEGINTERFERON%20BETA%2D1A&SponsorApplicant=BIOGEN%20IDEC%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,26,Cerdelga,eliglustat,2014-08-19,For the long-term treatment of adult patients with the Type 1 form of Gaucher diseasePress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205494&DrugName=CERDELGA&ActiveIngred=ELIGLUSTAT&SponsorApplicant=GENZYME%20CORP&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410585.htm,
2014,27,Keytruda,pembrolizumab,2014-09-04,For treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125514&DrugName=KEYTRUDA&ActiveIngred=PEMBROLIZUMAB&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm,
2014,28,Movantik,naloxegol,2014-09-16,To treat opioid-induced constipation in adults with chronic non-cancer pain.Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204760&DrugName=MOVANTIK&ActiveIngred=NALOXEGOL&SponsorApplicant=ASTRAZENECA%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm414620.htm,
2014,29,Trulicity,dulaglutide,2014-09-18,To treat adults with type 2 diabetes.Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125469&DrugName=TRULICITY&ActiveIngred=DULAGLUTIDE&SponsorApplicant=ELI%20LILLY%20AND%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm,
2014,30,Harvoni,ledipasvir/sofosbuvir,2014-10-10,To treat chronic hepatitis C virus (HCV) genotype 1 infectionPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205834&DrugName=HARVONI&ActiveIngred=LEDIPASVIR%3B%20SOFOSBUVIR&SponsorApplicant=GILEAD%20SCIENCES%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm,
2014,31,Akynzeo,netupitant and palonosetron,2014-10-10,To treat nausea and vomiting in patients undergoing cancer chemotherapyPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205718&DrugName=AKYNZEO&ActiveIngred=NETUPITANT%3B%20PALONOSETRON%20HYDROCHLORIDE&SponsorApplicant=HELSINN%20HLTHCARE&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418375.htm,
2014,32,Lumason,sulfur hexafluoride lipid microsphere,2014-10-10,For patients whose ultrasound image of the heart (echocardiograms) are hard to see with ultrasound wavesPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203684&DrugName=LUMASON&ActiveIngred=SULFUR%20HEXAFLUORIDE%20LIPID%2DTYPE%20A%20MICROSPHERES&SponsorApplicant=BRACCO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418509.htm,
2014,33,Ofev,nintedanib,2014-10-15,For the treatment of idiopathic pulmonary fibrosis (IPF)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205832&DrugName=OFEV&ActiveIngred=NINTEDANIB&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm,
2014,34,Esbriet,pirfenidone,2014-10-15,For the treatment of idiopathic pulmonary fibrosis (IPF)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=022535&DrugName=ESBRIET&ActiveIngred=PIRFENIDONE&SponsorApplicant=INTERMUNE%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm,
2014,35,Blincyto,blinatumomab,2014-12-03,To treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125557&DrugName=BLINCYTO&ActiveIngred=BLINATUMOMAB&SponsorApplicant=AMGEN&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm,
2014,36,Xtoro,finafloxacin otic suspension,2014-12-17,"To treat acute otitis externa, commonly known as swimmer’s earPress Release",https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206307&DrugName=XTORO&ActiveIngred=FINAFLOXACIN&SponsorApplicant=ALCON%20RES%20LTD&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427274.htm,
2014,37,Lynparza,olaparib,2014-12-19,To treat advanced ovarian cancerPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206162&DrugName=LYNPARZA&ActiveIngred=OLAPARIB&SponsorApplicant=ASTRAZENECA%20LP&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm,
2014,38,Viekira Pak,"(ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets)",2014-12-19,"To treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosisPress Release",https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206619&DrugName=VIEKIRA%20PAK&ActiveIngred=OMBITASIVR%3B%20PARITAPREVIR%3B%20RITONAVIR%3B%20DASABUVIR&SponsorApplicant=ABBVIE%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm,
2014,39,Zerbaxa,ceftolozane/tazobactam,2014-12-19,To treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI)Press Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206829&DrugName=ZERBAXA&ActiveIngred=CEFTOLOZANE%3BTAZOBACTAM&SponsorApplicant=CUBIST%20PHARMS%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm,
2014,40,Rapivab,peramivir,2014-12-19,To treat influenza infection in adultsPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206426&DrugName=RAPIVAB&ActiveIngred=PERAMIVIR&SponsorApplicant=BIOCRYST%20PHARMACEUTICALS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm,
2014,41,Opdivo,nivolumab,2014-12-22,To treat patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugsPress Release,https://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125554&DrugName=OPDIVO&ActiveIngred=NIVOLUMAB&SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052129/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm,
2015,1,Savaysa,edoxaban,2015-01-08,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problemPress ReleaseDrug Trials Snapshot (atrial fibrillation) Drug Trials Snapshot (venous thromboembolism),https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206316&DrugName=SAVAYSA&ActiveIngred=EDOXABAN&SponsorApplicant=DAIICHI%20SANKYO&ProductMktStatus=1&goto=Search.Label_ApprovalHistory;SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429523.htm,
2015,2,Cosentyx,secukinumab,2015-01-21,To treat adults with moderate-to-severe plaque psoriasisPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125504&DrugName=COSENTYX&ActiveIngred=SECUKINUMAB&SponsorApplicant=NOVARTIS%20PHARMS%20CORP&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm,
2015,3,Natpara,parathyroid horomone,2015-01-23,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidismPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125511&DrugName=NATPARA&ActiveIngred=PARATHYROID%20HORMONE&SponsorApplicant=NPS%20PHARMS%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431358.htm,
2015,4,Ibrance,palbociclib,2015-02-03,To treat advanced (metastatic) breast cancerPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207103&DrugName=IBRANCE&ActiveIngred=PALBOCICLIB&SponsorApplicant=PFIZER%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm,
2015,5,Lenvima,lenvatinib,2015-02-13,"To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).Press ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206947&DrugName=LENVIMA&ActiveIngred=LENVATINIB&SponsorApplicant=EISAI%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434288.htm,
2015,6,Farydak,panobinostat,2015-02-23,To treat patients with multiple myelomaPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205353&DrugName=FARYDAK&ActiveIngred=PANOBINOSTAT&SponsorApplicant=NOVARTIS%20PHARMS%20CORP&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm,
2015,7,Avycaz,ceftazidime-avibactam,2015-02-25,"To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options. Press ReleaseDrug Trials Snaphot (cIAI) Drug Trials Snapshot (cUTI)",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206494&DrugName=AVYCAZ&ActiveIngred=CEFTAZIDIME%3BAVIBACTAM&SponsorApplicant=CEREXA&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm,
2015,8,Cresembacapsuleinjection,isavuconazonium sulfate,2015-03-06,"To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infectionsPress Release Drug Trials Snapshot (aspergillosis)Drug Trials Snapshot (mucormycosis)",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207500&DrugName=CRESEMBA&ActiveIngred=ISAVUCONAZONIUM%20SULFATE&SponsorApplicant=ASTELLAS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437106.htm,
2015,9,Unituxin,dinutuximab,2015-03-10,To treat pediatric patients with high-risk neuroblastomaPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125516&DrugName=UNITUXIN&ActiveIngred=DINUTUXIMAB&SponsorApplicant=UNITED%20THERAP&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437460.htm,
2015,10,Cholbam,cholic acid,2015-03-17,"To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disordersPress ReleaseDrug Trials Snapshot (bile acid synthesis disorders)Drug Trials Snapshot (peroxisomal disorders)",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205750&DrugName=CHOLBAM&ActiveIngred=CHOLIC%20ACID&SponsorApplicant=ASKLEPION%20PHARMACEUTICALS%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm438572.htm,
2015,11,Corlanor,ivabradine,2015-04-15,To reduce hospitalization from worsening heart failure.Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206143&DrugName=CORLANOR&ActiveIngred=IVABRADINE%20HYDROCHLORIDE&SponsorApplicant=AMGEN%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm,
2015,12,Kybella,deoxycholic acid,2015-04-29,"To treat adults with moderate-to-severe fat below the chin, known as submental fatPress ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206333&DrugName=KYBELLA&ActiveIngred=DEOXYCHOLIC%20ACID&SponsorApplicant=KYTHERA%20BIOPHARMA%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm,
2015,13,Viberzi,eluxadoline,2015-05-27,To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206940&DrugName=VIBERZI&ActiveIngred=ELUXADOLINE&SponsorApplicant=FURIEX%20PHARMA%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.htm,
2015,14,Kengreal,canegrelor,2015-06-22,To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary intervention Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204958&DrugName=KENGREAL&ActiveIngred=CANGRELOR&SponsorApplicant=MEDICINES%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm452172.htm,
2015,15,Orkambi,lumacaftor 200 mg/ivacaftor 125 mg,2015-07-02,To treat cystic fibrosisPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206038&DrugName=ORKAMBI&ActiveIngred=LUMACAFTOR%2FIVACAFTOR&SponsorApplicant=VERTEX%20PHARMS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm,
2015,16,Entresto,sacubitril/valsartan,2015-07-07,To treat heart failurePress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207620&DrugName=ENTRESTO&ActiveIngred=SACUBITRIL%3BVALSARTAN&SponsorApplicant=NOVARTIS%20PHARMS%20CORP&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm,
2015,17,Rexulti,brexpiprazole,2015-07-10,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorderPress Release Drug Trials Snapshot (treatment of major depressive disorder)Drug Trials Snapshot (treatment of schizophrenia),https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205422&DrugName=REXULTI&ActiveIngred=BREXPIPRAZOLE&SponsorApplicant=OTSUKA%20PHARM%20CO%20LTD&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454647.htm,
2015,18,Praluent,alirocumab,2015-07-24,To treat certain patients with high cholesterolPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125559&DrugName=PRALUENT&ActiveIngred=ALIROCUMAB&SponsorApplicant=SANOFI%20AVENTIS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm,
2015,19,Odomzo,sonidegib,2015-07-24,"To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.Press ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205266&DrugName=ODOMZO&ActiveIngred=SONIDEGIB&SponsorApplicant=NOVARTIS%20PHARMS%20CORP&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm,
2015,20,Daklinza,daclatasvir,2015-07-24,To treat chronic hepatitis C virus (HCV) genotype 3 infectionsPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206843&DrugName=DAKLINZA&ActiveIngred=DACLATASVIR&SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455888.htm,
2015,21,Addyi,flibanserin,2015-08-18,"To treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal womenPress ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=022526&DrugName=ADDYI&ActiveIngred=FLIBANSERIN&SponsorApplicant=SPROUT%20PHARMACEUTICALS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm,
2015,22,Repatha,evolocumab,2015-08-27,To treat certain patients with high cholesterolPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125522&DrugName=REPATHA&ActiveIngred=EVOLOCUMAB&SponsorApplicant=AMGEN%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460082.htm,
2015,23,Varubi,rolapitant,2015-09-02,To prevent delayed phase chemotherapy-induced nausea and vomiting (emesis)Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206500&DrugName=VARUBI&ActiveIngred=ROLAPITANT&SponsorApplicant=TESARO%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460838.htm,
2015,24,Xuriden,uridine triacetate,2015-09-04,To treat patients with hereditary orotic aciduriaPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208169&DrugName=XURIDEN&ActiveIngred=URIDINE%20TRIACETATE&SponsorApplicant=WELLSTAT%20THERAP&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm457867.htm,
2015,25,Vraylar,cariprazine,2015-09-17,To treat schizophrenia and bipolar disorder in adultsPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204370&DrugName=VRAYLAR&ActiveIngred=CARIPRAZINE&SponsorApplicant=FOREST%20LABS%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463103.htm,
2015,26,Lonsurf,trifluridine and tipiracil,2015-09-22,To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapiesPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207981&DrugName=LONSURF&ActiveIngred=TRIFLURIDINE%3BTIPIRACIL&SponsorApplicant=TAIHO%20ONCOLOGY%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm,
2015,27,Tresiba,insulin degludec injection,2015-09-25,To improve blood sugar (glucose) control in adults with diabetes mellitusPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203314&DrugName=TRESIBA&ActiveIngred=INSULIN%20DEGLUDEC&SponsorApplicant=NOVO%20NORDISK%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm464321.htm,
2015,28,Aristada,aripiprazole lauroxil,2015-10-06,To treat adults with schizophreniaPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207533&DrugName=ARISTADA&ActiveIngred=ARIPIPRAZOLE%20LAUROXIL&SponsorApplicant=ALKERMES&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465801.htm,
2015,29,Praxbind,idarucizumab,2015-10-16,For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects. Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761025&DrugName=PRAXBIND&ActiveIngred=IDARUCIZUMAB&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm,
2015,30,Veltassa,patiromer for oral suspension,2015-10-21,"To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.Press ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205739&DrugName=VELTASSA&ActiveIngred=PATIROMER%20SORBITEX%20CALCIUM&SponsorApplicant=RELYPSA%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468546.htm,
2015,31,Yondelis,trabectedin,2015-10-23,To treat specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207953&DrugName=YONDELIS&ActiveIngred=TRABECTEDIN&SponsorApplicant=JANSSEN%20PRODS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm,
2015,32,Strensiq,asfotase alfa,2015-10-23,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP). Press ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125513&DrugName=STRENSIQ&ActiveIngred=ASFOTASE%20ALFA&SponsorApplicant=ALEXION%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468836.htm,
2015,33,Nucala,mepolizumab,2015-11-04,For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older.Press Release,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125526&DrugName=NUCALA&ActiveIngred=MEPOLIZUMAB&SponsorApplicant=GLAXOSMITHKLINE%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm,
2015,34,Genvoya,"a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide",2015-11-05,For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and olderPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207561&DrugName=GENVOYA&ActiveIngred=ELVITEGRAVIR%3BCOBICISTAT%3BEMTRICITABINE%3BTENOFOVIR%20ALAFENAMIDE&SponsorApplicant=GILEAD%20SCIENCES%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471300.htm,
2015,35,Cotellic,cobimetinib,2015-11-10,"To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)Press ReleaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206192&DrugName=COTELLIC&ActiveIngred=COBIMETINIB&SponsorApplicant=GENENTECH%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm,
2015,36,Tagrisso,osimertinib,2015-11-13,To treat certain patients with non-small cell lung cancerPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208065&DrugName=TAGRISSO&ActiveIngred=OSIMERTINIB&SponsorApplicant=ASTRAZENECA%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm,
2015,37,Darzalex,daratumumab,2015-11-16,To treat patients with multiple myeloma who have received at least three prior treatments.Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761036&DrugName=DARZALEX&ActiveIngred=DARATUMUMAB&SponsorApplicant=JANSSEN%20BIOTECH&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm,
2015,38,Ninlaro,ixazomib,2015-11-20,To treat people with multiple myeloma who have received at least one prior therapyPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208462&DrugName=NINLARO&ActiveIngred=IXAZOMIB%20CITRATE&SponsorApplicant=MILLENNIUM%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473771.htm,
2015,39,Portrazza,necitumumab,2015-11-24,To treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancerPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125547&DrugName=PORTRAZZA&ActiveIngred=NECITUMUMAB&SponsorApplicant=ELI%20LILLY%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474131.htm,
2015,40,Empliciti,elotuzumab,2015-11-30,To treat people with multiple myeloma who have received one to three prior medicationsPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761035&DrugName=EMPLICITI&ActiveIngred=ELOTUZUMAB&SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm,
2015,41,Kanuma,sebelipase alfa,2015-12-08,To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiencyPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125561&DrugName=KANUMA&ActiveIngred=SEBELIPASE%20ALFA&SponsorApplicant=ALEXION%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476013.htm,
2015,42,Alecensa,alectinib,2015-12-11,To treat ALK-positive lung cancerPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125561&DrugName=KANUMA&ActiveIngred=SEBELIPASE%20ALFA&SponsorApplicant=ALEXION%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm,
2015,43,Bridion,sugammadex,2015-12-15,To reverse effects of neuromuscular blocking drugs used during surgeryPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=022225&DrugName=BRIDION&ActiveIngred=SUGAMMADEX&SponsorApplicant=ORGANON%20USA%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477512.htm,
2015,44,Uptravi,selexipag,2015-12-22,To treat pulmonary arterial hypertensionPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207947&DrugName=UPTRAVI&ActiveIngred=SELEXIPAG&SponsorApplicant=ACTELION%20PHARMS%20LTD&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478599.htm,
2015,45,Zurampic,lesinurad,2015-12-22,To treat high blood uric acid levels associated with goutPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207988&DrugName=ZURAMPIC&ActiveIngred=LESINURAD&SponsorApplicant=ARDEA%20BIOSCIENCES%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052128/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478791.htm,
2016,1,Zepatier,elbasvir and grazoprevir,2016-01-28,To treat patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208261&DrugName=ZEPATIER&ActiveIngred=ELBASVIR%3BGRAZOPREVIR&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm,
2016,2,Briviact,brivaracetam,2016-02-18,To treat partial onset seizures in patients age 16 years and older with epilepsy.Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205836&DrugName=BRIVIACT&ActiveIngred=BRIVARACETAM&SponsorApplicant=UCB%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm,
2016,3,Anthim,obiltoxaximab,2016-03-18,To treat inhalational anthrax in combination with appropriate antibacterial drugs.Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125509&DrugName=ANTHIM&ActiveIngred=OBILTOXAXIMAB&SponsorApplicant=ELUSYS%20THERAPEUTICS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491470.htm,
2016,4,Taltz,ixekizumab,2016-03-22,To treat adults with moderate-to-severe plaque psoriasis. Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125521&DrugName=TALTZ&ActiveIngred=IXEKIZUMAB&SponsorApplicant=ELI%20LILLY%20AND%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm,
2016,5,Cinqair,reslizumab,2016-03-23,To treat severe asthmaPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761033&DrugName=CINQAIR&ActiveIngred=RESLIZUMAB&SponsorApplicant=TEVA%20RESPIRATORY%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491980.htm,
2016,6,Defitelio,defibrotide sodium,2016-03-30,To treat adults and children who develop hepatic veno-occlusive disease with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantationPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208114&DrugName=DEFITELIO&ActiveIngred=DEFIBROTIDE%20SODIUM&SponsorApplicant=GENTIUM%20SPA&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm493225.htm,
2016,7,Venclexta,venetoclax,2016-04-11,For chronic lymphocytic leukemia in patients with a specific chromosomal abnormalityPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208573&DrugName=VENCLEXTA&ActiveIngred=VENETOCLAX&SponsorApplicant=ABBVIE%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm,
2016,8,Nuplazid,pimavanserin,2016-04-29,To treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s diseasePress ReleaseDrug Trial Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207318&DrugName=NUPLAZID&ActiveIngred=PIMAVANSERIN%20TARTRATE&SponsorApplicant=ACADIA%20PHARMS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm,
2016,9,Tecentriq,atezolizumab,2016-05-18,"To treat urothelial carcinoma, the most common type of bladder cancerPress ReleaseDrug Trial Snapshot",https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761034&DrugName=TECENTRIQ&ActiveIngred=ATEZOLIZUMAB&SponsorApplicant=GENENTECH%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm,
2016,10,Zinbryta,daclizumab,2016-05-27,To treat multiple sclerosisPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761029&DrugName=ZINBRYTA&ActiveIngred=DACLIZUMAB&SponsorApplicant=BIOGEN&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm,
2016,11,Ocaliva,obeticholic acid,2016-05-27,"To treat rare, chronic liver diseasePress releaseDrug Trials Snapshot",https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=207999&DrugName=OCALIVA&ActiveIngred=OBETICHOLIC%20ACID&SponsorApplicant=INTERCEPT%20PHARMACEUTICALS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503964.htm,
2016,12,Axumin,fluciclovine F 18,2016-05-27,A  new diagnostic imaging agent to detect recurrent prostate cancerPress releaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208054&DrugName=AXUMIN&ActiveIngred=FLUCICLOVINE%20%2818F%29&SponsorApplicant=BLUE%20EARTH%20DIAGNOSTICS%20LTD&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503920.htm,
2016,13,NETSPOT,gallium Ga 68 dotatate,2016-06-01,A diagnostic imaging agent to detect rare neuroendocrine tumorsPress ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208547&DrugName=NETSPOT&ActiveIngred=GALLIUM%20GA%2068%20DOTATATE&SponsorApplicant=ADVANCED%20ACCELERATOR%20APPLICATIONS%20USA%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524.htm,
2016,14,Epclusa,sofosbuvir and velpatasvir,2016-06-28,To treat all six major forms of hepatitis C virus Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208341&DrugName=EPCLUSA&ActiveIngred=SOFOSBUVIR%3B%20VELPATASIVIR&SponsorApplicant=GILEAD%20SCIENCES%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm,
2016,15,Xiidra,lifitegrast ophthalmic solution,2016-07-11,To treat the signs and symptoms of dry eye diseasePress Release,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208073&DrugName=XIIDRA&ActiveIngred=LIFITEGRAST&SponsorApplicant=SHIRE%20DEV%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm510720.htm,
2016,16,Adlyxin,lixisenatide,2016-07-27,To improve glycemic control (blood sugar levels)Press Release,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=208471&DrugName=ADLYXIN&ActiveIngred=LIXISENATIDE&SponsorApplicant=SANOFI%2DAVENTIS%20US&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm,
2016,17,Exondys 51,eteplirsen,2016-09-19,To treat patients with Duchenne muscular dystrophy Press ReleaseDrug Trials Snapshot,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206488&DrugName=EXONDYS%2051&ActiveIngred=ETEPLIRSEN&SponsorApplicant=SAREPTA%20THERAPEUTICS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm,
2016,18,Lartruvo,olaratumab,2016-10-19,To treat adults with certain types of soft tissue sarcomaPress Release,https://wayback.archive-it.org/7993/20161022052127/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=761038&DrugName=LARTRUVO&ActiveIngred=OLARATUMAB&SponsorApplicant=ELI%20LILLY%20AND%20CO&ProductMktStatus=1&goto=Search.DrugDetails,https://wayback.archive-it.org//7993/20161022052127/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm,
2021,1,Verquvo,vericiguat,2021-01-19,"To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214377,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-verquvo
2021,2,Cabenuva,cabotegravir and rilpivirine (co-packaged),2021-01-21,"To treat HIV
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212888,https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cabenuva
2021,3,Lupkynis,voclosporin,2021-01-22,"To treat lupus nephritis
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213716,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lupkynis
2021,4,Tepmetko,tepotinib,2021-02-03,"To treat non-small cell lung cancer
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214096,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tepmetko
2021,5,Ukoniq,umbralisib,2021-02-05,"To treat marginal zone lymphoma and follicular lymphoma
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213176,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ukoniq-0
2021,6,Evkeeza,evinacumab-dgnb,2021-02-11,"To treat homozygous familial hypercholesterolemia
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761181,,
2021,7,Cosela,trilacicilib,2021-02-12,"To mitigate chemotherapy-induced myelosuppression in small cell lung cancer
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214200,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cosela
2021,8,Amondys 45,casimersen,2021-02-25,"To treat Duchenne muscular dystrophy
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213026,https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0,
2021,9,Nulibry,fosdenopterin,2021-02-26,"To reduce the risk of mortality in molybdenum cofactor deficiency Type A
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214018,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nulibry
2021,10,Pepaxto,melphalan flufenamide,2021-02-26,"To treat relapsed or refractory multiple myeloma
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214383,,
2021,11,Azstarys,"serdexmethylphenidate and
			dexmethylphenidate",2021-03-02,"To treat attention deficit hyperactivity disorder
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212994,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-azstarys
2021,12,Fotivda,tivozanib,2021-03-10,"To treat renal cell carcinoma
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212904,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-fotivda
2021,13,Ponvory,ponesimod,2021-03-18,"To treat relapsing forms of multiple sclerosis
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213498,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-ponvory
2021,14,Zegalogue,dasiglucagon,2021-03-22,"To treat severe hypoglycemia
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214231,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zegalogue
2021,15,Qelbree,viloxazine,2021-04-02,"To treat attention deficit hyperactivity disorder
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-qelbree
2021,16,Nextstellis,drospirenone and estetrol,2021-04-15,"To prevent pregnancy
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214154,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nextstellis
2021,17,Jemperli,dostarlimab-gxly,2021-04-22,"To treat endometrial cancer
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761174,https://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-endometrial-cancer-specific-biomarker,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-jemperli
2021,18,Zynlonta,loncastuximab tesirine-lpyl,2021-04-23,"To treat certain types of relapsed or refractory large B-cell lymphoma
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761196,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zynlonta
2021,19,Empaveli,pegcetacoplan,2021-05-14,"To treat paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215014,,
2021,20,Rybrevant,amivantamab-vmjw,2021-05-21,"To treat a subset of non-small cell lung cancer
Drug Trials Snapshot
Press Release",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761210,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-rybrevant
2021,21,Pylarify,piflufolastat F 18,2021-05-26,"To identify prostate-specific membrane antigen-positive lesions in prostate cancer
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214793,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pylarify
2021,22,Lumakras,sotorasib,2021-05-28,"To treat types of non-small cell lung cancer 
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214665,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lumakras
2021,23,Truseltiq,infigratinib,2021-05-28,"To treat cholangiocarcinoma whose disease meets certain criteria
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214622,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-truseltiq
2021,24,Lybalvi,olanzapine and samidorphan,2021-05-28,"To treat schizophrenia and certain aspects of bipolar I disorder
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213378,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lybalvi
2021,25,Brexafemme,ibrexafungerp,2021-06-01,"To treat vulvovaginal candidiasis
Drug Trials Snapshots",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214900,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brexafemme
2021,26,Aduhelm,aducanumab-avwa,2021-06-07,"To treat Alzheimer’s disease
Press Release
Drug Trials Snapshots",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761178,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aduhelm
2021,27,Rylaze,asparaginase erwinia chrysanthemi (recombinant)-rywn,2021-06-30,"To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen
Press Release
Drug Trials Snapshots",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761179,https://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rylaze
2021,28,Kerendia,finerenone,2021-07-09,"To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-kerendia
2021,29,Fexinidazole,fexinidazole,2021-07-16,"To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214429,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-fexinidazole
2021,30,Rezurock,belumosudil,2021-07-16,"To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214783,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezurock
2021,31,Bylvay,odevixibat,2021-07-20,"To treat pruritus
Drug Trials Snapshots",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215498,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-bylvay
2021,32,Saphnelo,anifrolumab-fnia,2021-07-30,"To treat moderate-to severe systemic lupus erythematousus along with standard therapy
Drug Trials Snapshots",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-saphnelo
2021,33,Nexviazyme,avalglucosidase alfa-ngpt,2021-08-06,"To treat late-onset Pompe disease
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761194,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pompe-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-nexviazyme
2021,34,Welireg,belzutifan,2021-08-13,"To treat von Hippel-Lindau disease under certain conditions
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215383,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-welireg
2021,35,Korsuva,difelikefalin,2021-08-23,"To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214916,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-korsuva
2021,36,Skytrofa,lonapegsomatropin-tcgd,2021-08-25,"To treat short stature due to inadequate secretion of endogenous growth hormone
Drug Trial Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761177,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-skytrofa
2021,37,Exkivity,mobocertinib,2021-09-15,"To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-exkivity
2021,38,Tivdak,tisotumab vedotin-tftv,2021-09-20,"To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Drug Trial Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761208,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tivdak
2021,39,Qulipta,atogepant,2021-09-28,"To prevent episodic migraines
Drug Trial Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215206,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-qulipta
2021,40,Livmarli,maralixibat,2021-09-29,"To treat cholestatic pruritus associated with Alagille syndrome
Drug Trial Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214662,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-livmarli
2021,41,Tavneos,avacopan,2021-10-07,"To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids
Drug Trial Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214487,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tavneos
2021,42,Scemblix,asciminib,2021-10-29,"To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-scemblix
2021,43,Besremi,ropeginterferon alfa-2b-njft,2021-11-12,"To treat polycythemia vera, a blood disease that causes the overproduction of red blood cells
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761166,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-blood-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-besremi
2021,44,Voxzogo,vosoritide,2021-11-19,"To improve growth in children five years of age and older with achondroplasia and open epiphyses
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214938,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-voxzogo
2021,45,Livtencity,maribavir,2021-11-23,"To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215596,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-livtencity
2021,46,Cytalux,pafolacianine,2021-11-29,"To help identify ovarian cancer lesions 
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214907,https://www.fda.gov/news-events/press-announcements/fda-approves-new-imaging-drug-help-identify-ovarian-cancer-lesions,
2021,47,Tezspire,tezepelumab-ekko,2021-12-17,"To treat severe asthma as an add-on maintenance therapy
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761224,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tezspire
2021,48,Vyvgart,efgartigimod alfa-fcab,2021-12-17,"To treat generalized myasthenia gravis
Press Release
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761195,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-vyvgart
2021,49,Leqvio,inclisiran,2021-12-22,"To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapy
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214012,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-leqvio
2021,50,Adbry,tralokinumab-ldrm,2021-12-27,"To treat moderate-to-severe atopic dermatitis
Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761180,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-adbry
2022,1,Quviviq,daridorexant,2022-01-07,"To treat insomnia
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-quviviq
2022,2,Cibinqo,abrocitinib,2022-01-14,"To treat refractory, moderate-to-severe atopic dermatitis
Drug Trials Snapshot",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213871,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cibinqo
2022,3,Kimmtrak,tebentafusp-tebn,2022-01-25,"To treat unresectable or metastatic uveal melanoma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kimmtrak
2022,4,Vabysmo,faricimab-svoa,2022-01-28,"To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vabysmo
2022,5,Enjaymo,sutimlimab-jome,2022-02-04,"To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf?utm_medium=email&utm_source=govdelivery,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-enjaymo
2022,6,Pyrukynd,mitapivat,2022-02-17,"To treat hemolytic anemia in pyruvate kinase deficiency
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-pyrukynd
2022,8,Ztalmy,ganaxolone,2022-03-18,"To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ztalmy
2022,9,Opdualag,nivolumab and relatlimab-rmbw,2022-03-18,"To treat unresectable or metastatic melanoma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-opdualag
2022,10,Pluvicto,lutetium (177Lu) vipivotide tetraxetan,2022-03-23,"To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
Drug Trials Snapshot",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833,,https://www.fda.gov/drugs/drug-safety-and-availability/drug-trials-snapshots-pluvicto
2022,11,Vivjoa,oteseconazole,2022-04-26,"To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vivjoa
2022,12,Camzyos,mavacamten,2022-04-28,"To treat certain classes of obstructive hypertrophic cardiomyopathy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-camzyos
2022,13,Voquezna,"vonoprazan, amoxicillin, and clarithromycin",2022-05-03,"To treat Helicobacter pylori infection
Drug Trials Snapshot",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215152,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-voquezna-triple-pak-voquezna-dual-pak
2022,14,Mounjaro,tirzepatide,2022-05-13,"To improve blood sugar control in diabetes, in addition to diet and exercise 
Press Release (FDA Archive)
Drug Trials Snapshot",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866,https://www.fda.govhttps://public4.pagefreezer.com/browse/FDA/30-06-2023T13:23//news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mounjaro
2022,15,Vtama,tapinarof,2022-05-23,"To treat plaque psoriasis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vtama
2022,16,Amvuttra,vutrisiran,2022-06-13,"To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf,,
2022,17,Xenpozyme,Olipudase alfa,2022-08-31,"To treat Acid Sphingomyelinase Deficiency
Press Release (FDA Archive)
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf,https://www.fda.govhttps://public4.pagefreezer.com/content/FDA/30-06-2023T13:23//news-events/press-announcements/fda-approves-first-treatment-acid-sphingomyelinase-deficiency-rare-genetic-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xenpozyme
2022,18,Spevigo,spesolimab-sbzo,2022-09-01,"To treat generalized pustular psoriasis flares
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-spevigo
2022,19,Daxxify,daxibotulinumtoixnA-lanm,2022-09-07,"To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-daxxify
2022,20,Sotyktu,deucravacitinib,2022-09-09,"To treat moderate-to-severe plaque psoriasis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sotyktu
2022,21,Rolvedon,eflapegrastim,2022-09-09,"To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761148Orig1s000Corrected_lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rolvedon
2022,22,Terlivaz,terlipressin,2022-09-14,"To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-terlivaz
2022,23,Elucirem,gadopiclenol,2022-09-21,"To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-elucirem
2022,24,Omlonti,oomidenepag isopropyl ophthalmic solution,2022-09-22,"To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-omlonti
2022,25,Relyvrio,sodium phenylbutyrate/taurursodiol,2022-09-29,"To treat amyotrophic lateral sclerosis (ALS)
Press Release (FDA Archive)
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf,https://www.fda.govhttps://public4.pagefreezer.com/content/FDA/30-06-2023T13:23//news-events/press-announcements/fda-approves-new-treatment-option-patients-als,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-relyvrio
2022,26,Lytgobi,futibatinib,2022-09-30,"To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lytgobi
2022,27,Imjudo,tremelimumab,2022-10-21,"To treat unresectable hepatocellular carcinoma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-imjudo
2022,28,Tecvayli,teclistamab-cqyv,2022-10-25,"To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tecvayli
2022,29,Elahere,mirvetuximab soravtansine-gynx,2022-11-14,"To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf,,
2022,30,Tzield,teplizumab-mzwv,2022-11-18,"To delay the onset of stage 3 type 1 diabetes
Press Release (FDA Archive)
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf,https://www.fda.govhttps://public4.pagefreezer.com/content/FDA/30-06-2023T13:23//news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tzield
2022,31,Rezlidhia,olutasidenib,2022-12-01,"To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezlidhia
2022,32,Krazati,adagrasib,2022-12-12,"To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-krazati
2022,33,Sunlenca,lenacapavir,2022-12-22,"To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations
Press Release (FDA Archive)
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf,https://www.fda.govhttps://public4.pagefreezer.com/content/FDA/30-06-2023T13:23//news-events/press-announcements/fda-approves-new-hiv-drug-adults-limited-treatment-options,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sunlenca
2022,34,Lunsumio,mosunetuzumab-axgb,2022-12-22,"To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lunsumio
2022,35,Xenoview,hyperpolarized Xe-129,2022-12-23,"To evaluate pulmonary function and imaging
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xenoview
2022,36,Briumvi,ublituximab-xiiy,2022-12-28,"To treat relapsing forms of multiple sclerosis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-briumvi
2022,37,NexoBrid,anacaulase-bcdb,2022-12-28,"To remove eschar in adults with deep partial thickness or full thickness thermal burns
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-nexobrid
2022,38,Vonjo,pacritinib,2022-02-28,"To treat adult patients with a rare type of bone marrow disorder called myelofibrosis with platelet counts below 50,000/µL
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vonjo
2023,1,Leqembi,lecanemab-irmb,2023-01-06,"To treat Alzheimer’s disease
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-leqembi
2023,2,Brenzavvy,bexagliflozin,2023-01-20,"To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brenzavvy
2023,3,Jaypirca,pirtobrutinib,2023-01-27,"To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-jaypirca
2023,4,Orserdu,elacestrant,2023-01-27,"To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orserdu
2023,5,Jesduvroq,daprodustat,2023-02-01,"To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216951s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-jesduvroq
2023,6,Lamzede,velmanase alfa-tycv,2023-02-16,"To treat non-central nervous system manifestations of alpha-mannosidosis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761278s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lamzede
2023,7,Filspari,sparsentan,2023-02-17,"To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf,,https://www.fda.gov/drugs/drug-trials-snapshots-filspari
2023,8,Skyclarys,omaveloxolone,2023-02-28,"To treat Friedrich’s ataxia
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-skyclarys
2023,9,Zavzpret,zavegepant,2023-03-09,"To treat migraine
Drug Trails Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zavzpret
2023,10,Daybue,trofinetide,2023-03-10,"To treat Rett syndrome
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217026s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-daybue
2023,11,Zynyz,retifanlimab-dlwr,2023-03-22,"To treat metastatic or recurrent locally advanced Merkel cell carcinoma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zynyz
2023,12,Rezzayo,rezafungin,2023-03-22,"To treat candidemia and invasive candidiasis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezzayo
2023,13,Joenja,leniolisib,2023-03-24,"To treat activated phosphoinositide 3-kinase delta syndrome
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217759s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-joenja
2023,14,Qalsody,tofersen,2023-04-25,"To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-qalsody
2023,15,Elfabrio,pegunigalsidase alfa-iwxj,2023-05-09,"To treat confirmed Fabry disease
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-elfabrio
2023,16,Veozah,fezolinetant,2023-05-12,"To treat moderate to severe hot flashes caused by menopause
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-veozah
2023,17,Miebo,perfluorhexyloctane,2023-05-18,To treat signs and symptoms of dry eye disease,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf,,
2023,18,Epkinly,epcoritamab-bysp,2023-05-19,"To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
Drug Trials Snapshots",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-epkinly
2023,19,Xacduro,"sulbactam, durlobactam",2023-05-23,"To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
Press Release
Drug Trials Snapshots",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xacduro
2023,20,Paxlovid,"nirmatrelvir, ritonavir",2023-05-25,"To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-paxlovid
2023,21,Posluma,flotufolastat F 18,2023-05-25,"To use with positron emission tomography imaging in certain patients with prostate cancer
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216023s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-posluma
2023,22,Inpefa,sotagliflozin,2023-05-26,"To treat heart failure
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216203s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-inpefa
2023,23,Columvi,glofitamab-gxbm,2023-06-15,"To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-columvi
2023,24,Litfulo,ritlecitinib,2023-06-23,"To treat severely patchy hair loss
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-litfulo
2023,25,Rystiggo,rozanolixizumab-noli,2023-06-26,"To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rystiggo
2023,26,Ngenla,somatrogon-ghla,2023-06-27,"To treat growth failure due to inadequate secretion of endogenous growth hormone
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761184Orig1s000Corrected_lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ngenla
2023,27,Beyfortus,nirsevimab-alip,2023-07-17,"To prevent respiratory syncytial virus (RSV) lower respiratory tract disease
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-beyfortus
2023,28,Vanflyta,quizartinib,2023-07-20,"To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216993s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vanflyta
2023,29,Xdemvy,lotilaner,2023-07-25,"To treat Demodex blepharitis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217603s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xdemvy
2023,30,Zurzuvae,zuranolone,2023-08-04,"To treat postpartum depression 
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217369s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zurzuvae
2023,31,Izervay,avacincaptad pegol,2023-08-04,"To treat geographic atrophy secondary to age-related macular degeneration
Drug Trials Snapshots: IZERVAY",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217225s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-izervay
2023,32,Talvey,talquetamab-tgvs,2023-08-09,"To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-talvey
2023,33,Elrexfio,elranatamab-bcmm,2023-08-14,"To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345Orig1s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-elrexfio
2023,34,Sohonos,palovarotene,2023-08-16,"To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sohonos
2023,35,Veopoz,pozelimab-bbfg,2023-08-18,"To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-veopoz
2023,36,Aphexda,motixafortide,2023-09-08,"To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217159s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aphexda
2023,37,Ojjaara,momelotinib,2023-09-15,"To treat intermediate or high-risk myelofibrosis in adults with anemia
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ojjaara
2023,38,Exxua,gepirone,2023-09-22,To treat major depressive disorder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf,,
2023,39,Pombiliti,cipaglucosidase alfa-atga,2023-09-28,"To treat late-onset Pompe disease
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761204s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-pombiliti
2023,40,Rivfloza,nedosiran,2023-09-29,"To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rivfloza
2023,41,Velsipity,etrasimod,2023-10-12,"To treat moderately to severely active ulcerative colitis in adults
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-velsipity
2023,42,Zilbrysq,zilucoplan,2023-10-17,"To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zilbrysq
2023,43,Bimzelx,bimekizumab,2023-10-17,"To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-bimzelx
2023,44,Agamree,vamorolone,2023-10-26,"To treat Duchenne muscular dystrophy
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-agamree
2023,45,Omvoh,mirikizumab-mrkz,2023-10-26,"To treat ulcerative colitis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-omvoh
2023,46,Loqtorzi,toripalimab-tpzi,2023-10-27,To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf,,
2023,47,Fruzaqla,fruquintinib,2023-11-08,"To treat refractory, metastatic colorectal cancer
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-fruzaqla
2023,48,Defencath,"taurolidine, heparin",2023-11-15,"To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214520s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-defencath
2023,49,Augtyro,repotrectinib,2023-11-15,"To treat ROS1-positive non-small cell lung cancer
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-augtyro
2023,50,Ryzneuta,efbemalenograstim alfa-vuxw,2023-11-16,"To treat neutropenia
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761134s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ryzneuta
2023,51,Truqap,capivasertib,2023-11-16,"To treat breast cancer that meets certain disease criteria
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-truqap
2023,52,Ogsiveo,nirogacestat,2023-11-27,"To treat adults with progressing desmoid tumors who require systemic treatment
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217677s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ogsiveo
2023,53,Fabhalta,iptacopan,2023-12-05,"To treat paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218276s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-fabhlata
2023,54,Filsuvez,birch triterpenes,2023-12-18,"To treat wounds associated with dystrophic and junctional epidermolysis bullosa
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215064s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-filsuvez
2023,55,Wainua,eplontersen,2023-12-21,"To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217388s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-wainua
2024,1,Zelsuvmi,berdazimer,2024-01-05,"To treat molluscum contagiosum
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217424s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zelsuvmi
2024,2,Exblifep,"cefepime, enmetazobactam",2024-02-22,"To treat complicated urinary tract infections
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-exblifep
2024,3,Letybo,letibotulinumtoxinA-wlbg,2024-02-29,"To temporarily improve the appearance of moderate-to-severe glabellar lines
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-letybo
2024,4,Tevimbra,tislelizumab-jsgr,2024-03-13,"To treat unresectable or metastatic esophageal squamous cell carcinoma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra
2024,5,Rezdiffra,resmetirom,2024-03-14,"To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
Press Release",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease,
2024,6,Tryvio,aprocitentan,2024-03-19,"To treat hypertension
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tryvio
2024,7,Duvyzat,givinostat,2024-03-21,"To treat Duchenne muscular dystrophy in individuals aged 6 years and older
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217865Orig1s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-duvyzat
2024,8,Winrevair,sotatercept-csrk,2024-03-26,"To treat pulmonary arterial hypertension
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-winrevair
2024,9,Vafseo,vadadustat,2024-03-27,To treat anemia due to chronic kidney disease,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215192s000lbl.pdf,,
2024,10,Voydeya,danicopan,2024-03-29,"To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218037s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-voydeya
2024,11,Zevtera,ceftobiprole medocaril sodium,2024-04-03,"To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
Press Release
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218275s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zevtera
2024,12,Lumisight,pegulicianine,2024-04-17,To use as an optical imaging agent for the detection of cancerous tissue,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214511s000lbl.pdf,,
2024,13,Anktiva,nogapendekin alfa inbakicept-pmln,2024-04-22,"To treat bladder cancer
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761336s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-anktiva
2024,14,Ojemda,tovorafenib,2024-04-23,"To treat relapsed or refractory pediatric low-grade glioma
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218033s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ojemda
2024,15,Xolremdi,mavorixafor,2024-04-26,"To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218709s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xolremdi
2024,16,Imdelltra,tarlatamab-dlle,2024-05-16,"To treat extensive stage small cell lung cancer
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-imdelltra
2024,17,Rytelo,imetelstat,2024-06-06,"To treat low- to intermediate-1 risk myelodysplastic syndromes
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217779s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rytelo
2024,18,Iqirvo,elafibranor,2024-06-10,"To treat primary biliary cholangitis in combination with ursodeoxycholic acid
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-iqirvo
2024,19,Sofdra,sofpironium,2024-06-18,"To treat primary axillary hyperhidrosis
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217347s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sofdra
2024,20,Piasky,crovalimab-akkz,2024-06-20,"To treat paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761388s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-piasky
2024,21,Ohtuvayre,ensifentrine,2024-06-26,"To treat chronic obstructive pulmonary disease
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217389s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ohtuvayre
2024,22,Kisunla,donanemab-azbt,2024-07-02,"To treat Alzheimer’s disease
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kisunla
2024,23,Leqselvi,deuruxolitinib,2024-07-25,To treat severe alopecia areata,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217900Orig1s000correctedlbl.pdf,,
2024,24,Voranigo,vorasidenib,2024-08-06,To treat Grade 2 astrocytoma or oligodendroglioma,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,,
2024,25,Yorvipath,palopegteriparatide,2024-08-09,"To treat hypoparathyroidism
Drug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216490s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-yorvipath
2024,26,Nemluvio,nemolizumab-ilto,2024-08-12,"To treat prurigo nodularis
Drug Trials Snapshots",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761390s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nemluvio
2024,27,Livdelzi,seladelpar,2024-08-14,To treat primary biliary cholangitis (PBC),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf,,
2024,28,Niktimvo,axatilimab-csfr,2024-08-14,To treat chronic graft-versus-host disease (cGVHD),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdf,,
2024,29,Lazcluze,lazertinib,2024-08-19,To treat non-small cell lung cancer,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbl.pdf,,
2024,30,Ebglyss,lebrikizumab-lbkz,2024-09-13,To treat moderate-to-severe atopic dermatitis,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761306Orig1s000correctedlbl.pdf,,
2024,31,Miplyffa,arimoclomol,2024-09-20,"To treat Niemann-Pick disease type C
Press Release",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c,
2024,32,Aqneursa,levacetylleucine,2024-09-24,"To treat Niemann-Pick disease type C
Press Release",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219132s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c,
2024,33,Cobenfy,xanomeline and trospium chloride,2024-09-26,"To treat schizophrenia
Press Release",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216158s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia,
2024,34,Flyrcado,flurpiridaz F 18,2024-09-27,A radioactive diagnostic drug to evaluate for myocardial ischemia and infarction,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215168s000lbl.pdf,,
2024,35,Itovebi,inavolisib,2024-10-10,To treat locally advanced or metastatic breast cancer,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s001lbl.pdf,,
2024,36,Hympavzi,marstacimab-hncq,2024-10-11,"To prevent or reduce bleeding episodes related to hemophilia A or B
Press Release",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761369s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hemophilia-or-b,
2024,37,Vyloy,zolbetuximab-clzb,2024-10-18,To treat gastric or gastroesophageal junction adenocarcinoma,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf,,
2024,38,Orlynvah,"sulopenem etzadroxil, probenecid",2024-10-25,To treat uncomplicated urinary tract infections (uUTI),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213972s000lbl.pdf,,
